Title: Longitudinal lung function assessment of patients hospitalised with COVID-19 using ^{1}H and [129]Xe lung MRI

Authors: Laura C Saunders[1], Guilhem J Collier[1], Ho-Fung Chan[1], Paul J C Hughes[1], Laurie J Smith[1], James Watson[2], James Meiring[2], Zoë Gabriel[2], Thomas Newman[2], Megan Plowright[2], James A Eaden[1], Jody Bray[1], Helen Marshall[1], David J Capener[1], Leanne Armstrong[1], Jennifer Rodgers[1], Martin Brook[1], Alberto M Biancardi[1], Madhwesha R Rao[1], Graham Norquay[1], Oliver Rodgers[1], Ryan Munro[1], Neil J Stewart[1], Allan Lawrie[1], Gisli Jenkins[3], James Grist[4], Fergus Gleeson[4], Frederick Wilson[5*], Anthony Cahn[5], Andrew J Swift[1], Smitha Rajaram[2], Gary H Mills[1], Lisa Watson[2], Paul J Collini[1], Rod Lawson[2], A A Roger Thompson[1], and Jim M Wild[1]

1 Department of Infection, Immunity; Cardiovascular Disease, University of Sheffield, Sheffield, United Kingdom

2 Sheffield Teaching Hospitals, NHS Foundation TRUST, Sheffield, United Kingdom,

3 National Heart and Lung Institute, Imperial College London

4 Department of Radiology, Oxford NHS Foundation Trust, Oxford, United Kingdom,

5 GlaxoSmithKline, Stevenage, United Kingdom

* at the time of the study

Corresponding author: Jim Wild

Email address: j.m.wild@sheffield.ac.uk

Phone: +44 114 215 9141

Abstract

Introduction: Microvascular abnormalities and impaired ^{129}Xe gas transfer have been observed in patients with COVID-19. The progression of pathophysiological pulmonary changes during the post-acute period in these patients remains unclear.

Methods: Patients who were hospitalised due to COVID-19 pneumonia underwent a pulmonary ^{1}H and ^{129}Xe MRI protocol at 6, 12, 25 and 50 weeks after hospital admission. The imaging protocol included: ultra-short echo time, dynamic contrast enhanced lung perfusion, ^{129}Xe lung ventilation, ^{129}Xe diffusion weighted and ^{129}Xe 3D spectroscopic imaging of gas exchange.

Results: 9 patients were recruited and underwent MRI at 6 (n=9), 12 (n=9), 25 (n=6) and 50 (n=3) weeks after hospital admission. At 6 weeks after hospital admission, patients demonstrated impaired ^{129}Xe gas transfer (RBC:M) but normal lung microstructure (ADC, Lm$_D$). Minor ventilation abnormalities present in four patients were largely resolved in the 6–25 week period. At 12 week follow up, all patients with lung perfusion data available (n=6) showed an increase in both pulmonary blood volume and flow when compared to 6 weeks, though this was not statistically significant. At 12 and 25 week follow up, significant improvements in ^{129}Xe gas transfer were observed compared to 6-week examinations, however ^{129}Xe gas transfer remained abnormally low.

Conclusions: This study demonstrates that multinuclear MRI is sensitive to functional pulmonary changes in the follow up of patients who were hospitalised with COVID-19. Persistent impairment of xenon transfer may represent a physiological mechanism underlying ongoing symptoms in some patients and may indicate damage to the pulmonary microcirculation.

Introduction

In patients hospitalised with pneumonia due to SARS-CoV-2 infection, the existing literature and clinical experience suggest that there is considerable overlap in clinical presentation with typical pneumonia and acute respiratory distress syndrome (ARDS), with patients exhibiting hyper-inflammation and progressive hypoxaemia. However, patients with severe COVID-19 also show evidence of an inflammatory and thrombotic vasculopathy with endothelial dysfunction and excessive blood flow to collapsed lung tissue[1-3]. Abnormal pulmonary vasoregulation has been observed in patients in the acute phase of COVID-19[1] and may be a pathophysiological mechanism contributing to the progressive hypoxemia seen in these patients. The medium and long-term outcomes and complications of microvascular abnormalities alongside pulmonary scarring in patients who have been hospitalised due to COVID-19 are currently unknown.

Lung MRI with hyperpolarised ^{129}Xe gas allows direct, regionally sensitive measurements of lung ventilation and gas diffusion within the lung airspace (diffusion weighted MRI, DW-MRI). DW-MRI provides a quantitative assessment of acinar airway dimensions. The derived apparent diffusion coefficient (ADC) provides 3D in vivo information of the underlying lung microstructure, and has been shown to be highly sensitive to changes in lung microstructure in patients with emphysema[4] and fibrotic lung disease[5]. In addition to ADC, mathematical models of hyperpolarised gas diffusion within the lungs, can be used to derive estimates of mean acinar airway dimensions (LmD) analogous to mean linear intercept length obtained through histology[6].

In addition, ^{129}Xe is soluble in the lung tissue membrane (M) and in the red blood cells (RBC), and the signal from ^{129}Xe in these dissolved compartments can be distinguished spectroscopically. The ratio of the ^{129}Xe MRI signal observed in the lung airspaces (gas), the lung membrane and bound to the red blood cells can thus be determined with magnetic resonance spectroscopic imaging. In particular, the ratio of the ^{129}Xe signal in the RBC:M, RBC:gas and M:gas have been used to probe the transfer of gas between the airspace, membrane and blood[7, 8]. RBC:M has been shown to be highly sensitive to gas transfer limitation and longitudinal assessment of change in interstitial, emphysematous and pulmonary vascular diseases[9-11].

An early study from Wuhan, China with ^{129}Xe MRI showed reduced gas transfer to the RBC in 13 patients scanned 14-34 days after discharge from hospital following acute COVID-19, and a small but significant increase in lung ventilation defects when compared to healthy subjects[12]. Reduced xenon gas transfer has been shown to persist in patients hospitalised with COVID-19 pneumonia 24 weeks after discharge from hospital and it has been suggested that this may provide an explanation for prolonged breathlessness (a Long-COVID symptom) in patients[13].

It is currently unclear whether lung perfusion abnormalities or alveolar/interstitial endothelial changes, or a combination of both, are driving the reduced xenon gas transfer and breathlessness seen in patients after COVID-19. Lung perfusion imaging has been proposed as a key triage tool to evaluate small vessel injury and residual blood clot in patients who have had COVID-19[14]. Dynamic contrast enhanced (DCE) ^{1}H lung MRI allows the assessment of lung perfusion without exposing the participant to ionising radiation and is therefore well suited to patient follow-up studies. In one patient who was hospitalised due to COVID-19, 44% of the lung demonstrated a delayed or absent contrast signal-enhancement peak[15]. In another study of 28 people with persistent dyspnea after COVID-19, patients demonstrated significantly longer mean pulmonary time-to-peak (TTP) when compared with healthy controls (preprint)[16]. This evidence suggests lung perfusion MRI has sensitivity to detect microvascular perfusion abnormalities in patients who have had COVID-19.

Furthermore, ^{1}H lung MRI can also provide structural lung images with good visualisation of the lung parenchyma using ultra-short echo time (UTE) imaging. UTE imaging has been reported to be of comparable quality to CT imaging for evaluating lung structural changes due to COVID-19 in a cohort of 23 acute COVID-19 patients[17].

In this study we utilised a comprehensive, multinuclear MRI protocol which combines hyperpolarised ^{129}Xe imaging methods sensitive to ventilation, lung microstructure (DW-MRI) and gas exchange (dissolved xenon spectroscopic imaging) alongside ^{1}H DCE perfusion and UTE lung structural imaging to assess pathophysiological changes in patients who had been hospitalised with COVID-19 pneumonia, during the post-acute period.

Methods

Participants

Patients with acute COVID-19 pneumonia and no previously diagnosed respiratory disease (excluding mild asthma) were recruited from Sheffield Teaching Hospitals respiratory and infectious diseases wards from November 2020. Recruitment for this study is ongoing, with follow-up ^{29}Xe and ^{1}H lung MRI examinations at approximately 6, 12, 24 and 52 weeks after COVID-19 infection. Patients were required to meet the following criteria:

(i) a positive SARS-CoV-2 result from a nasal/pharyngeal or respiratory sample;
(ii) hospitalisation with a diagnosis of pneumonia (chest X-ray or CT scan consistent with COVID-19 infection);
(iii) subsequently developed onset oxygenation impairment (SpO2≤93% on room air and requiring additional oxygen);
(iv) did not show evidence of interstitial lung damage on CT or MRI structural imaging at 12 weeks after hospital admission, as judged by a clinical radiologist.

Patients with evidence of interstitial lung damage at 12 weeks after hospital admission were recruited into the parallel UKILD study[18]. Standard MRI exclusion criteria were applied to all subjects. In addition, patients were excluded if they were unable to tolerate a test inhalation of ^{129}Xe gas according to supervising clinicians' judgement, or if they had a chest size exceeding the ^{129}Xe chest coil diameter (38 cm).

MRI acquisition

Patients underwent scanning on either a GE HDx 1.5T (N=7) or a GE 450W 1.5T (GE Healthcare, Milwaukee, WI, USA) (N=2) MRI scanner. Each patient underwent MRI examinations on the same scanner for baseline visits and follow-up. See Figure 1 for an illustrative diagram of lung MRI methods utilised within this study.

^{129}Xe doses were polarised to ~30% using a custom-built spin-exchange optical pumping polariser[19]. ^{129}Xe images were acquired with the patient in a flexible quadrature transmit/receive vest coil (Clinical MR Solutions, Brookfield, Wisconsin, USA). Patients' vital signs were monitored throughout the MRI examination. MR imaging parameters are detailed in the online supplement, Supplementary Table 1.

A structural ^{1}H scan was acquired after inhalation of a 1L bag of air to match the lung inflation state of the subsequent xenon sequences. ^{129}Xe ventilation images were acquired after inhalation of a 1L

mixture of [129]Xe and N_2 using a 3D imaging sequence[20] detailed in the online supplement, Supplementary Table 1.

[129]Xe DW-MRI to assess alveolar micro-structural change was acquired after inhalation of 1L mixture of [129]Xe and N_2 using a 3D spoiled gradient echo (SPGR) multiple b-value sequence with compressed sensing[21].

3D spectroscopic imaging of the gas and dissolved phase xenon resonances (dissolved xenon in lung membrane, M, and in blood red blood cells, RBC) was acquired using 1L of hyperpolarised [129]Xe[22].

[1]H MRI was acquired using an 8-element cardiac array (GE Healthcare, Milwaukee, WI, USA). UTE images were acquired with a 3D radial sequence during 8 minutes of free-breathing with prospective respiratory bellows gating on expiration[23].

3D variable flip angle SPGR images[24, 25] were acquired with flip angles of 2°, 4°, 10° and 30°, to allow for the correction of lung T_1 and proton density. DCE lung perfusion MRI was acquired using time-resolved SPGR imaging with view sharing and parallel imaging. A half dose (0.05mL/kg) of Gadovist (Bayer) was administered at an injection rate of 4ml/s followed by a 10ml saline flush at 4ml/s. Patients were advised to hold their breath for as long as possible and breathe shallowly thereafter.

Image analysis

Qualitative assessments of the UTE ^{1}H structural, [129]Xe ventilation and DCE lung perfusion images were made by two radiologists with 10 and 14 years' experience. UTE images were assessed for parenchymal changes, and ventilation and perfusion images were assessed for defects.

Metrics of ventilation defect (VDP), low ventilation percentage (VP), normal VP, and hyper VP for each patient were calculated using linear binning (see online supplement). The coefficient of variation (CV) of the segmented lung ventilation images was also calculated from the [129]Xe ventilation images as metrics of ventilation heterogeneity.

Maps of [129]Xe apparent diffusion coefficient (ADC) and mean diffusive length scale (Lm_D) from a stretched exponential model of [129]Xe gas diffusion in the lungs were calculated on a voxel-by-voxel basis[26].

Maps of gas transfer ratios (RBC:M, RBC:gas, M:gas) were calculated from 3D spectroscopic imaging. The transverse relaxation time, T_2^*, of the RBC and M spectroscopic peaks was also calculated.

Mean values of all global metrics were calculated for each patient.

Pulmonary function tests

Where possible, pulmonary function tests (PFTs) were acquired on the same day as the MRI examination at each visit. Spirometry and transfer factor were performed and from these tests, the metrics FEV1, FVC, FEV1/FVC, TL_{CO} and K_{CO} were calculated and presented as Z-scores and % predicted using GLI reference ranges[27, 28].

Statistical analysis

Global MRI metrics from visits 1, 2 and 3 were compared using a Friedman test with Dunn's pairwise post hoc tests and a Bonferroni correction for multiple testing was applied. Data are presented as median (range), unless otherwise stated. Missing data were excluded from statistical analysis on a test-by-test basis.

The within-subject correlation between RBC:M and DCE metrics was calculated using the analysis of covariance method [29].

Statistical analysis was performed using IBM SPSS Statistics 27 (SPSS, New York, USA). A p-value of <0.05 was considered statistically significant.

Age and sex matched healthy volunteer metrics

Median ADC and Lm_D values for an age and sex matched control cohort were determined by retrospective analysis of previously published data[6]. 11 subjects from this previously published work were selected based on age and sex from a cohort of 23 whilst blinded to MRI metrics, such that the control cohort had a median age of 63 (40-70) years and were 27% female.

Median RBC:M, RBC:gas and M:gas for an age and sex matched control cohort were determined by retrospective analysis of a healthy cohort data set, with controls chosen based on age and sex whilst blinded to MRI metrics. 12 subjects were selected who had a median age of 57 (41-68) years and were 33% female.

Results

Of the 75 patients approached, 32 were confirmed eligible. 14/32 patients did not show any signs of interstitial lung damage at 12 weeks and were therefore included as part of this study. 9/14 patients had follow-up examinations and were therefore included in the analysis in this paper. 5/75 approached participants were excluded due to their chest size exceeding the size of the xenon MRI coil and 2/75 approached participants were excluded due to poor health. A flow diagram of the number of individuals at each stage of the study and further details on reasons for non-participation in the study are available in the online supplement, Supplementary Figure 1.

3/9 patients were female. Median (range) patient age, height and weight were 57 (42-72) years, 173 (170-191)cm and 101 (84-112)kg. Visit 1 (n=9) occurred 6 (4-12) weeks after hospital admission, visit 2 (n=9) occurred 12 (11-22) weeks after hospital admission and visit 3 (n=7) occurred 25 (23-28) weeks after hospital admission. 3 patients had MRI data available for visit 4 which occurred 50 (49-51) weeks after hospital admission. Patients were admitted to hospital for 6 (2-15) days. Further patient demographic data is available in Table 1.

UTE and [129]Xe MRI were successfully acquired in all patients at all visits. DCE lung perfusion imaging was successfully acquired in 6/9 patients at visit 1, 8/9 patients at visit 2, 6/7 patients at visit 3 and 2/3 patients at visit 4, due to patient difficulties with the required breath hold for this acquisition.

Figure 2 shows representative slices from the UTE images, RBC:M maps, [129]Xe ventilation images, and DCE pulmonary blood flow maps for each patient at visit 1 and visit 2. Figure 3 shows plots of ventilation, dissolved phase [129]Xe, and DCE lung perfusion metrics for each patient at each visit.

Median metrics and statistical comparisons of metrics at visit 1, visit 2 and visit 3 are shown in Table 2.

^{129}Xe MRI

Ventilation: At visit 1, small ventilation defects were visible in the lung periphery in four patients (patient 1, patient 3, patient 4 and patient 6), no other patients had visible lung ventilation defects. At visit 2 and 3, the ventilation defects observed in patients 1, 3, 4 and 6 had improved, with small defects still visible particularly in patient 3, see Figures 3 and Supplementary Figure 2. At visit 1, VDP was 1.6 (0.6-3.9)%, at visit 2 VDP was 1.3(0.7-2.6)% and at visit 3 VDP was 1.2(0.4-2.1)%. VDP was significantly lower at visit 3 when compared to visit 1 (p=0.010). Ventilation CV was also significantly lower at visit 3 compared to visit 1 (p=0.048), see Table 2.

DW-MRI (alveolar microstructure): Median ADC and Lm_D at each visit are reported in Table 2. No significant longitudinal changes in ADC and Lm_D were seen between visits 1, 2 and 3. Median ADC and Lm_D were within the interquartile range (IQR) of age and sex matched control data (age and sex matched control data: median ADC=0.0360 cm^{2}s^{-1}, IQR=0.005cm^{2}s^{-1}; Median Lm_D =289μm, IQR=27μm) at all visits.

Dissolved xenon (gas exchange): The global RBC:M ratio significantly increased at visit 2 compared to visit 1, p=0.048. RBC:M at visit 1 was 0.22(0.15-0.37) and at visit 2 was 0.25(0.18-0.41). No subjects showed a decrease in RBC:M at visit 2 when compared to visit 1, see Figures 3 and 4. RBC:M was also significantly increased at visit 3 when compared to visit 1, with a median RBC:M of 0.25(0.19-0.44), p=0.048. There was no significant change between visit 2 and visit 3.

At visits 3 and 4, some patients showed continued improvement (see Figures 3 and 4), while others maintained an abnormal RBC:M during the 25-50 week period.

There was no significant longitudinal change in RBC:gas or M:gas. Figure 5 shows box-plots of the RBC:M, RBC:gas and M:gas for patients at each visit, with reference box plots of age and sex matched control data (control RBC:M median=0.39, IQR=0.13; RBC:gas median=0.0034, IQR=0.0006; M:gas median=0.0088, IQR=0.0021). The number of patients who had RBC:M below the IQR of the age and sex matched healthy volunteers was 8/9 at visit 1, 7/9 at visit 2 and 5/9 at visit 3.

M T_2^* also showed a significant longitudinal decrease at visit 2 compared to visit 1, p=0.004. No other significant changes in RBC or M T_2^*were seen, see the online supplement Supplementary Figure 3.

^{1}H MRI

Structural changes: The UTE image of patient 3 showed abnormal linear parenchymal changes at visit 1, which improved but remained abnormal at visits 2 and 3. Patients 2, 6, 7 and 8 showed air trapping on their UTE image at visit 1, which resolved at visit 2 for patients 6, 7 and 8. Patient 2 continued to have air trapping present at visit 3. The UTE images of patients 1, 4, 5 and 9 were normal at all visits, see the online supplement, Supplementary Table 2.

DCE (Perfusion): Patient 1 showed a segmental perfusion defect at visit 1 which was resolved at visit 2. No other patients showed any substantial regional perfusion defects. Median pulmonary blood volume and flow increased in all patients (n=6) at visit 2 compared to visit 1, however the increase was not statistically significant. For the 6 patients with DCE MRI at visit 1 and 2, pulmonary blood volume was 37.8 (11.7-53.5) ml/100ml at visit 1 and 47.6 (15.0-60.2)ml/100ml at visit 2, and

pulmonary blood flow was 76.9 (19.6-107.2)ml/100ml/min at visit 1 and 91.1 (30.7-109.5)ml/100ml/min at visit 2, see Figure 3.

Correlation of RBC:M and DCE metrics: The analysis of covariance showed a statistically significant correlation between RBC:M and pulmonary blood volume within patients, across visits 1-3. Correlation coefficient=0.61, p=0.026, see online supplement Supplementary Figure 4. No statistically significant correlations between RBC:M and other DCE perfusion metrics were found.

PFTs: PFT data was available for 6/9 patients at visit 1, 6/9 patients at visit 2 and 7/9 patients at visit 3, all Z-scores and % predicted data are shown in Table 3. There was a median of 0 days (mean: 1.7 days, range: 0-23 days) between MRI and PFT tests.

TL_{CO} Z-score (TL_{CO}-Z) was -1.66 (-1.96, 0.66) at visit 1, -0.88 (-1.49, 0.68) at visit 2 and -0.47 (-1.51, 0.90) at visit 3. 3/6 patients had abnormal TL_{CO}-Z(<1.64) at visit 1. No patients had abnormal TL_{CO}-Z at visit 2 or 3.

One patient (patient 5) had abnormally low FVC at visit 1 and high FEV1/FVC Z-score at visit 2. No other PFT metrics were outside a normal range at any visits.

Of the 4 patients with TL_{CO}-Z available at visits 1 and 2, all patients showed increased TL_{CO}-Z at visit 2 compared to visit 1. Of the 5 patients with TL_{CO}-Z available at visits 2 and 3 there was an increase in TL_{CO}-Z in 3 patients at visit 3.

Discussion

This study has used a comprehensive multinuclear MRI protocol to assess pathophysiological pulmonary changes in patients who were hospitalised with COVID-19 in the post-acute period. The preliminary findings demonstrate that these patients had impaired gas transfer (RBC:M), however measures of lung microstructure (ADC and Lm_D) were normal. Four of nine patients had small ventilation defects at 6 weeks which largely resolved by 25 weeks. Despite significant increases in [129]Xe gas transfer (RBC:M) at 12-25 weeks when compared to 6 weeks, median[129]Xe gas transfer in these patients remains lower than expected at 25-50 weeks, compared to an age and sex matched healthy cohort. These initial results indicate that some COVID-19 patients show continued abnormalities in [129]Xe gas transfer at 25-50 weeks after hospitalisation, while others demonstrate consistent improvement across the same time frame with RBC:M within the normal range at 25-50 weeks. PFT data from this cohort showed abnormal TL_{CO}-Z in 3/6 patients at visit 1, with TL_{CO}-Z in the normal range for all patients at visits 2 and 3.

Median patient ADC and Lm_D were within the age and sex matched reference range at visits 1 and 2[21], with no significant change at visit 2, indicating normal lung microstructure in 9 patients who had COVID-19 but did not have signs of interstitial lung damage on structural imaging. This paper specifically excluded patients with signs of interstitial lung damage, however it has been reported that at 6 weeks after hospitalisation 4.8% of patients had radiological changes compatible with early interstitial lung damage[30], and DW-MRI has been shown previously to be sensitive to changes in alveolar geometry in patients with interstitial lung damage[22]. Therefore, further work using DW-MRI in patients with pulmonary fibrosis on CT due to COVID-19 is warranted to evaluate changes in the lung microstructure of these patients and is the subject of an ongoing study (UKILD)[18].

Minor ventilation heterogeneity and defects were present in this cohort shortly after acute illness, which improved over time, consistent with the previous findings by both Grist et al.[13] and Li et

al.[12]. Li et al., reported a ventilation defect percentage (VDP) of 5.9% (range: 1.6-9.9%) in patients discharged after hospitalisation due to COVID-19 (14-34 days after discharge) which was significantly higher than in healthy volunteers (3.7%). Grist et al., reported well ventilated lungs in patients after having had COVID-19 (mean time after discharge: 24 weeks) although the imaging used to assess ventilation in that study was of poorer spatial resolution so may have missed mild ventilation heterogeneity. Overall, our study and the findings from previous literature suggest it is unlikely that impaired lung ventilation is the primary cause of ongoing symptoms after the acute stage of COVID-19 and that the pathophysiology is not primarily of the airways.

Li et al reported a mean RBC:M of 0.279±0.04 at discharge in patients hospitalised with COVID-19 pneumonia (RF excitation FA=90°, TR= 100ms). Grist et al reported a mean RBC:M of 0.3±0.1 at 24 weeks after discharge (RF excitation FA=40°, TR= 40ms). Although not directly comparable due to differences in imaging parameters, our findings are in accordance with these previously reported low RBC:M values between hospital discharge and 24 weeks post discharge. RBC:gas and M:gas did not show significant longitudinal change, implying that the change in RBC:M was a combined effect of changes in both M and RBC. A significant reduction in M T_2^* at visit 2 was also found. The physiological mechanisms behind changes in M T_2^* are not well established and for further discussion, see the online supplement.

A limitation of this study is that not all patients had DCE lung perfusion imaging. However, all patients with DCE data available showed an increase in regional pulmonary blood flow and volume between visits 1 and 2, despite only one having a substantial perfusion defect. This may indicate microvascular improvements at 12 weeks. The analysis of covariance between RBC:M and pulmonary blood volume, showed that an individuals' increase in RBC:M was significantly and positively associated with an increase in pulmonary blood volume. This indicates that microvascular recovery may be partially driving changes in RBC:M in these patients. In parallel a concomitant reduction in M signal due to resolution of post-infection endothelial inflammation could contribute to the increase in RBC:M with time.

The main limitation of this study is the relatively small number of participants which was largely due to the challenging nature of recruiting patients for scanning after a recent hospitalisation due to COVID-19. The numbers recruited limit correlations with symptoms, activity and lung function and also the statistical tests used to test for change. A potential source of bias in this study is that 5 patients who were potentially eligible for the study were excluded due to chest size exceeding the size of the xenon MRI coil. Previous data from age and sex matched healthy volunteer cohorts were included in this paper, to illustrate where metrics deviated from normal values. Age dependence of gas transfer is a well-documented physiological phenomenon[27] that has also been demonstrated in chemical shift saturation recovery MR spectroscopy experiments using hyperpolarised ^{129}Xe[31]. Therefore, age matching of healthy controls is necessary for accurate comparison with patients. Further work is warranted to establish the relationship between dissolved phase ^{129}Xe imaging metrics with age and sex.

This paper has focused on the longitudinal analysis of the global whole lung metrics derived from the functional imaging techniques. Work in progress entails regional analysis of the individual functional techniques and investigation of the anatomical distribution and their regional correlation.

In conclusion, the initial results from this ongoing longitudinal study show that 6 weeks after hospital admission with COVID-19 pneumonia, patients demonstrated impaired ^{129}Xe gas transfer (RBC:M), but normal lung microstructure (ADC, Lm$_D$). Small ventilation defects and heterogeneity present in

some patients largely resolved in the 6-25 week period. Improvements in an individual's RBC:M correlated with an increase in an individual's lung perfusion.

At 12 week follow up, improvements in xenon gas transfer (RBC:M) were seen, though RBC:M remained abnormal for the majority of patients. At 25-50 week follow up, patient RBC:M changes were heterogenous, with some patients showing continued improvement whilst for others, RBC:M remained abnormal.

We believe this to be the first follow up study of such patients with such an extensive range of functional lung imaging techniques and the findings demonstrate the sensitivity and complementary nature of functional MRI to follow up post COVID lung pathophysiology in a clinical setting.

Tables:

Table 1: Patient demographic data. MRC: medical research council. Ex-smokers all had ≤15 pack years.

	Group	Number of patients
Age	<50	2
	50-59	3
	60-69	3
	70-79	1
Sex	Male	6
	Female	3
BMI	25-29.9	3
	30-39.9	5
	40+	1
Oxygen requirement during hospital admission	Low flow	8
	CPAP	1
ISARIC 4C score[32]	1-4	3
	5-8	5
	>8	1
Length of stay	1-5	4
	6-9	4
	>10	1
MRC Dyspnoea Scale (1-5) – 6 weeks	1	6
	2	2
	Not available	1
MRC Dyspnoea Scale (1-5) – 3 months	1	7
	2	1
	3	1
	Not available	0
Comorbidities 4C score[32]	0	4
	1	4
	3	1
Smoking History	Never smokers	4
	Ex-smokers	5

Table 2: Median metrics for all MRI parameters at visits 1, 2 and 3. Data are presented as median (range) of all patients with available data for each visit. If a Friedman test determined that there was a significant difference between at least two variables, p-values are shown for Dunn's pairwise post hoc tests with a Bonferroni correction for multiple testing.

	Visit 1	Visit 2	Visit 3	Adj. p-value (visit 1 and visit 2)	Adj. p-value (visit 2 and visit 3)	Adj. p-value (visit 1 and visit 3)

ADC (cm^{2}s^{-1})	0.0344 (0.309-0.0373)	0.0327 (0.0281-0.0386)	0.340 (0.310-0.364)	-	-	-
Lm$_D$ (μm)	281 (260-300)	273 (251-301)	278 (263-290)	-	-	-
RBC:M	0.22 (0.15-0.37)	0.25 (0.18-0.41)	0.25 (0.19-0.44)	0.048	1.00	0.048
RBC:gas	0.0026 (0.0018-0.0039)	0.0030 (0.0019-0.0038)	0.0026 (0.0020-0.0040)	-	-	-
M:gas	0.0113 (0.0091-0.0125)	0.0114 (0.0081-0.0179)	0.0101 (0.0091 – 0.0113)	-	-	-
M T$_2^*$ (ms)	2.58 (2.46-2.68)	2.47 (2.38-2.58)	2.42 (2.36-2.56)	0.004	0.326	0.326
RBC T$_2^*$ (ms)	2.20 (2.05-2.48)	2.16 (2.01-2.49)	2.16 (2.06-2.32)	-	-	-
DCE PBV (ml/100ml)	37.8 (11.7-53.5)	47.6 (15.0-60.2)	45.3 (36.3-58.4)	-	-	-
SD PBV (ml/100ml)	45.8 (7.5-28.5)	21.3 (13.0-24.8)	23.8 (17.9-25.7)	-	-	-
IQR PBV (ml/100ml)	25.1 (7.8-34.9)	27.8 (10.5-36.1)	35.9 (24.2-41.5)	-	-	-
DCE PBF (ml/100ml/min)	76.9 (19.6-107.2)	90.2 (30.7 – 109.5)	71.1 (60.3-117.7)	-	-	-
SD PBF (ml/100ml/min)	45.8 (11.5-58.8)	54.5 (32.0-75.0)	48.6 (35.6-69.5)	-	-	-
IQR PBF (ml/100ml/min)	54.0 (14.1-61.3)	59.2 (25.5-102.9)	59.0 (43.2-78.7)	-	-	-
Median MTT (s)	6.5 (5.6-8.0)	7.3 (6.4-8.0)	7.1 (3.5-9.9)	-	-	-
SD MTT (s)	1.3 (0.9-1.6)	1.21 (0.6-2.6)	1.3 (0.5-2.2)	-	-	-
IQR MTT (s)	1.3 (1.1-2.0)	1.6 (0.7-3.1)	1.3 (0.6-3.5)	-	-	-
VDP (%)	1.6 (0.6-3.9)	1.3 (0.7-2.6)	1.2 (0.4-2.1)	0.855	0.184	0.010
Normal VP (%)	76.4 (62.5-77.7)	76.9 (72.3-86.2)	78.9 (67.4-81.5)	-	-	-
Low VP (%)	12.5 (10.0-15.4)	11.9 (8.9-13.1)	10.9 (9.1-14.8)	-	-	-
Hyper VP (%)	11.7 (9.5-18.3)	11.0 (4.2-13.3)	9.7 (7.9-15.8)	-	-	-
Lung ventilation CV	29.0 (27.5-37.1)	28.8 (22.3-32.2)	26.9 (25.6-34.1)	0.326	1.00	0.048

ADC: apparent diffusion coefficient. Lm$_D$: mean diffusive length scale. RBC: red blood cell. M: membrane. DCE: dynamic contrast enhanced. PBV: pulmonary blood volume. PBF: pulmonary blood

flow. MTT: mean transit time. VDP: ventilation defect percentage. VP: ventilation percentage. CV: coefficient of variation.

Table 3 : All available PFT data (% predicted and Z-score) at visits 1, 2 and 3.

	FEV1		FVC		FEV1/FVC		TL$_{CO}$		K$_{CO}$	
	%pred	Z-score	%pred	Z-score	%pred	Z-score	%pred	Z-score	%pred	Z-score
Patient 1										
Visit 1	-	-	-	-	-	-	-	-	-	-
Visit 2	109.45	0.65	119.74	1.28	90.77	-1.03	111.06	0.68	99.30	-0.05
Visit 3	116.10	1.11	118.93	1.22	97.03	-0.35	108.22	0.51	97.94	0.14
Patient 2										
Visit 1	-	-	-	-	-	-	-	-	-	-
Visit 2	-	-	-	-	-	-	-	-	-	-
Visit 3	106.00	0.45	103.62	0.26	101.54	0.22	88.40	-0.82	91.33	-0.82
Patient 3										
Visit 1	91.17	-0.58	89.82	-0.69	101.02	0.11	74.99	-1.62	87.35	-0.83
Visit 2	89.80	-0.67	91.53	-0.57	97.58	-0.26	78.77	-1.35	89.59	-0.67
Visit 3	102.59	0.17	96.27	-0.25	106.10	0.68	88.42	-0.71	91.19	-0.57
Patient 4										
Visit 1	-	-	-	-	-	-	-	-	-	-
Visit 2	91.52	-0.56	88.30	-0.79	103.47	0.38	93.29	-0.41	101.21	0.08
Visit 3	93.12	-0.45	90.78	-0.62	102.54	0.26	98.52	-0.47	98.52	-0.09
Patient 5										
Visit 1	81.12	-1.11	70.42	-1.86	114.41	1.50	68.76	-1.96	91.44	-0.52
Visit 2	92.06	-.047	78.03	-1.37	117.39	1.80	75.56	-1.49	95.87	-0.25
Visit 3	82.49	-1.03	75.00	-1.56	109.36	0.95	75.27	-1.51	106.94	0.41
Patient 6										
Visit 1	103.46	0.25	105.10	0.36	98.40	-0.20	111.14	0.66	115.70	1.01
Visit 2	-	-	-	-	-	-	-	-	-	-
Visit 3	103.07	0.22	107.02	0.49	107.11	-0.44	113.36	0.79	113.87	0.89
Patient 7										
Visit 1	90.14	-0.76	82.66	-1.32	108.89	1.21	73.10	-1.93	94.69	-0.38
Visit 2	90.69	-0.72	78.03	-1.37	108.17	1.16	79.97	-1.40	101.37	0.10
Visit 3	-	-	-	-	-	-	-	-	-	-
Patient 8										
Visit 1	100.32	0.02	97.24	-0.20	103.10	0.39	75.29	-1.70	90.01	-0.69
Visit 2	-	-	-	-	-	-	-	-	-	-
Visit 3	-	-	-	-	-	-	-	-	-	-
Patient 9										
Visit 1	116.30	1.33	110.58	0.82	104.38	0.61	96.74	-0.24	101.45	0.11
Visit 2	110.86	0.88	106.05	0.47	103.62	0.52	107.67	0.53	115.77	1.10
Visit 3	119.32	1.58	116.49	1.27	101.48	0.22	113.33	0.90	109.41	0.67

Figures

Figure 1: Illustrative diagram showing how the lung MRI techniques employed in this paper measure to lung perfusion, ventilation, lung microstructure (acinar airway dimensions) and xenon gas transfer (the transfer of xenon between the airspace, membrane, and RBCs). A) shows these techniques in a healthy alveolus. B) shows a possible interpretation of the findings of this paper in patients who have had COVID-19, with reduced RBC:M due to damage to pulmonary microcirculation but preserved acinar airway dimensions.

Figure 2: Example ultra-short echo time (UTE) images, RBC:M maps, [129]Xe ventilation images and maps of pulmonary blood flow at visit 1 and visit 2, for each patient. The white arrow shows a segmental perfusion defect visible at visit 1 which improves at visit 2. UTE: ultra-short echo time. RBC: red blood cell. M: membrane. PBF: pulmonary blood flow.

Figure 3: Spaghetti plots of ventilation, dissolved phase xenon and DCE lung perfusion metrics at visits 1-4. VDP: ventilation defect percentage. CV: coefficient of variation of lung ventilation. RBC: red blood cell. M: membrane.

Figure 4: Lung RBC:M maps in three patients with four MRI visits at 6, 12, 25 and 50 weeks after hospital admission. Mean RBC:M at each visit is shown. RBC: red blood cell. M: Membrane.

Figure 5: Box plots of gas transfer ratios from patients at visit 1, visit 2 and visit 3 as well as metrics from an age and sex matched healthy cohort. RBC: red blood cell. TP: tissue/plasma. o denotes data >1.5 IQR, ★ denotes data >3 IQR.

References

1. Lang, M., et al., *Pulmonary Vascular Manifestations of COVID-19 Pneumonia.* Radiol Cardiothorac Imaging, 2020. **2**(3): p. e200277.
2. Loo, J., D.A. Spittle, and M. Newnham, *COVID-19, immunothrombosis and venous thromboembolism: biological mechanisms.* Thorax, 2021. **76**(4): p. 412-420.
3. Attaway, A.H., et al., *Severe covid-19 pneumonia: pathogenesis and clinical management.* BMJ, 2021. **372**: p. n436.
4. Kaushik, S.S., et al., *Diffusion-Weighted Hyperpolarized Xe-129 MRI in Healthy Volunteers and Subjects With Chronic Obstructive Pulmonary Disease.* Magnetic Resonance in Medicine, 2011. **65**(4): p. 1155-1165.
5. Chan, H.F., et al., *Airway Microstructure in Idiopathic Pulmonary Fibrosis: Assessment at Hyperpolarized He-3 Diffusion-weighted MRI.* Radiology, 2019. **291**(1): p. 223-229.
6. Petersson-Sjogren, M., et al., *Airspace Dimension Assessment (AiDA) by inhaled nanoparticles: benchmarking with hyperpolarised (129)Xe diffusion-weighted lung MRI.* Sci Rep, 2021. **11**(1): p. 4721.
7. Marshall, H., et al., *In vivo methods and applications of xenon-129 magnetic resonance.* Prog Nucl Magn Reson Spectrosc, 2021. **122**: p. 42-62.
8. Wang, Z.Y., et al., *Using hyperpolarized Xe-129 gas-exchange MRI to model the regional airspace, membrane, and capillary contributions to diffusing capacity.* Journal of Applied Physiology, 2021. **130**(5): p. 1398-1409.
9. Weatherley, N.D., et al., *Hyperpolarised xenon magnetic resonance spectroscopy for the longitudinal assessment of changes in gas diffusion in IPF.* Thorax, 2019. **74**(5): p. 500-502.
10. Wang, J.M., et al., *Using hyperpolarized (129)Xe MRI to quantify regional gas transfer in idiopathic pulmonary fibrosis.* Thorax, 2018. **73**(1): p. 21-28.
11. Myc, L., et al., *Characterisation of gas exchange in COPD with dissolved-phase hyperpolarised xenon-129 MRI.* Thorax, 2021. **76**(2): p. 178-181.
12. Li, H., et al., *Damaged lung gas exchange function of discharged COVID-19 patients detected by hyperpolarized (129)Xe MRI.* Sci Adv, 2021. **7**(1).
13. Grist, J.T., et al., *Hyperpolarized (129)Xe MRI Abnormalities in Dyspneic Patients 3 Months after COVID-19 Pneumonia: Preliminary Results.* Radiology, 2021. **301**(1): p. E353-E360.
14. Dhawan, R.T., et al., *Beyond the clot: perfusion imaging of the pulmonary vasculature after COVID-19.* Lancet Respir Med, 2021. **9**(1): p. 107-116.
15. Rysz, S., et al., *COVID-19 pathophysiology may be driven by an imbalance in the renin-angiotensin-aldosterone system.* Nat Commun, 2021. **12**(1): p. 2417.
16. Yu, J., et al., *Lung Perfusion Disturbances Detected with MRI in Non-Hospitalized Post-COVID-19 Individuals with Dyspnea 3 -13 Months after the Acute Disease.* medRxiv, 2022: p. 2022.01.25.22269717.
17. Yang, S., et al., *Clinical Potential of UTE-MRI for Assessing COVID-19: Patient- and Lesion-Based Comparative Analysis.* J Magn Reson Imaging, 2020. **52**(2): p. 397-406.
18. Wild, J.M., et al., *Understanding the burden of interstitial lung disease post-COVID-19: the UK Interstitial Lung Disease-Long COVID Study (UKILD-Long COVID).* BMJ Open Respir Res, 2021. **8**(1).
19. Norquay, G., et al., *^{129}Xe-Rb Spin-Exchange Optical Pumping with High Photon Efficiency.* Phys Rev Lett, 2018. **121**(15): p. 153201.
20. Stewart, N.J., et al., *Feasibility of human lung ventilation imaging using highly polarized naturally abundant xenon and optimized three-dimensional steady-state free precession.* Magn Reson Med, 2015. **74**(2): p. 346-52.
21. Chan, H.F., et al., *3D diffusion-weighted (129) Xe MRI for whole lung morphometry.* Magn Reson Med, 2018. **79**(6): p. 2986-2995.

22. Collier, G.J., et al., *Dissolved (129) Xe lung MRI with four-echo 3D radial spectroscopic imaging: Quantification of regional gas transfer in idiopathic pulmonary fibrosis.* Magn Reson Med, 2021. **85**(5): p. 2622-2633.

23. Johnson, K.M., et al., *Optimized 3D ultrashort echo time pulmonary MRI.* Magn Reson Med, 2013. **70**(5): p. 1241-50.

24. Li, K.L., et al., *Improved 3D quantitative mapping of blood volume and endothelial permeability in brain tumors.* J Magn Reson Imaging, 2000. **12**(2): p. 347-57.

25. Cheng, H.L. and G.A. Wright, *Rapid high-resolution T(1) mapping by variable flip angles: accurate and precise measurements in the presence of radiofrequency field inhomogeneity.* Magn Reson Med, 2006. **55**(3): p. 566-74.

26. Chan, H.F., et al., *Finite element simulations of hyperpolarized gas DWI in micro-CT meshes of acinar airways: validating the cylinder and stretched exponential models of lung microstructural length scales.* Magn Reson Med, 2021. **86**(1): p. 514-525.

27. Stanojevic, S., et al., *Official ERS technical standards: Global Lung Function Initiative reference values for the carbon monoxide transfer factor for Caucasians.* Eur Respir J, 2017. **50**(3).

28. Quanjer, P.H., et al., *Multi-ethnic reference values for spirometry for the 3-95-yr age range: the global lung function 2012 equations.* Eur Respir J, 2012. **40**(6): p. 1324-43.

29. Bland, J.M. and D.G. Altman, *Calculating correlation coefficients with repeated observations: Part 2--Correlation between subjects.* BMJ, 1995. **310**(6980): p. 633.

30. Myall, K.J., et al., *Persistent Post-COVID-19 Interstitial Lung Disease. An Observational Study of Corticosteroid Treatment.* Ann Am Thorac Soc, 2021. **18**(5): p. 799-806.

31. Stewart, N.J., et al., *Experimental validation of the hyperpolarized (129) Xe chemical shift saturation recovery technique in healthy volunteers and subjects with interstitial lung disease.* Magn Reson Med, 2015. **74**(1): p. 196-207.

32. Knight, S.R., et al., *Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: development and validation of the 4C Mortality Score.* BMJ, 2020. **370**: p. m3339.